Compare KZIA & FTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KZIA | FTF |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 216.2M |
| IPO Year | 2002 | 2003 |
| Metric | KZIA | FTF |
|---|---|---|
| Price | $8.09 | $5.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.33 | N/A |
| AVG Volume (30 Days) | 229.9K | ★ 270.5K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $5.29 |
| 52 Week High | $17.40 | $6.29 |
| Indicator | KZIA | FTF |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 40.64 |
| Support Level | $6.72 | $5.29 |
| Resistance Level | $8.18 | $5.90 |
| Average True Range (ATR) | 0.67 | 0.06 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 48.51 | 50.00 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective, is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.